UNITE Study: Understanding New Interventions With GBM ThErapy
Status:
Terminated
Trial end date:
2020-03-03
Target enrollment:
Participant gender:
Summary
The objective of this study was to evaluate the effect of several ophthalmologic prophylactic
treatment strategies for the management of ocular side effects (OSEs) in participants with
epidermal growth factor receptor (EGFR)-amplified glioblastoma (GBM) who were being treated
with depatuxizumab mafodotin (ABT-414).